Ifex
(ifosfamide)ApprovedSmall molecule
Ifosfamide is a chemotherapy drug used to treat various cancers including testicular cancer, lymphomas, and sarcomas. It works by damaging cancer cell DNA to prevent them from growing and dividing.[2] Ifex is currently approved and in use across 60 indications[4].[1]
Ifex is one of 866 small molecule programs targeting Glioma. It is currently in Approved.
60
Indications
307
Total Trials
31
Active Trials
865
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 58 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ifex
BBaxter Healthcare Corporation
Approved
Halaven
EisaiPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Avastin
RochePreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Paracetamol
GSKPreclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma38 trials
Show 35 more trials
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Terminated·—·Phase 2·NCT00126191·10 enrolled
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled
Soft Tissue Sarcoma25 trials
Show 22 more trials
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Unknown status·EEuropean Paediatric Soft Tissue Sarcoma Study Group·Phase 3·NCT00334854·250 enrolled
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02808247·80 enrolled
Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
Terminated·—·Phase 2·NCT00544778·7 enrolled
Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00030784·28 enrolled
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002641·350 enrolled
Acute Lymphoblastic Leukemia13 trials
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Show 10 more trials
Osteosarcoma13 trials
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00245011·11 enrolled
Show 10 more trials
Germ Cell Tumor10 trials
Show 7 more trials
56 more indications
Neuroblastoma7 trials
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Completed·—·Phase 3·NCT00002802·500 enrolled
Show 4 more trials
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
Completed·—·Phase 2·NCT00165139·20 enrolled
Diffuse Large B-Cell Lymphoma7 trials
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting·—·Phase 2·NCT04665765·41 enrolled
Show 4 more trials
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting·—·Phase 1/2·NCT02628405·30 enrolled
Leukemia5 trials
Rhabdomyosarcoma5 trials
Ewing sarcoma4 trials
Stem Cell Transplantation4 trials
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Completed·—·Phase 1·NCT00002854·33 enrolled
Show 1 more trial
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
Completed·—·Phase 2·NCT00002931·48 enrolled
Small Cell Lung Cancer4 trials
Breast Cancer4 trials
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
Completed·—·Phase 2·NCT00006260·36 enrolled
Show 1 more trial
Chemotherapy3 trials
Non-Small Cell Lung Cancer3 trials
Anaplastic Large Cell Lymphoma3 trials
Newly Diagnosed2 trials
Bone Marrow Transplantation2 trials
Cervical Cancer2 trials
NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB
Unknown status·—·Phase 3·NCT02422563·534 enrolled
Advanced Sarcoma2 trials
Radiation Therapy2 trials
Ewing's Sarcoma1 trial
Efficacy and Safety1 trial
Advanced Cancer1 trial
Peritoneal Cancer1 trial
Penile Cancer1 trial
Brain Tumor1 trial
Primitive Neuroectodermal Tumor1 trial
Autologous Stem Cell Transplantation1 trial
Patients With Advanced Solid Tumors1 trial
Lymphoblastic Lymphoma1 trial
Second-line Therapy1 trial
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
Active, not recruiting·—·Phase 2·NCT03016871·78 enrolled
Recurrent Sarcoma1 trial
Neoadjuvant Chemotherapy1 trial
Chronic Myelomonocytic Leukemia1 trial
Central Nervous System Germ Cell Tumor1 trial
Stem Cell Transplant1 trial
T-cell acute lymphoblastic leukemia1 trial
Vomiting1 trial
Refractory Solid Tumors1 trial
Squamous Cell Carcinoma1 trial
B-cell Malignancies1 trial
Children1 trial
Advanced Solid Tumors1 trial
Recurrent Cancer1 trial
Prognosis1 trial
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099188·27 enrolled
Lung Cancer1 trial
Metastatic Solid Tumors1 trial
Locally Advanced1 trial
Hypofractionated Radiotherapy1 trial
Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment
Unknown status·—·Phase 2·NCT02812654·70 enrolled
Relapsed or Refractory1 trial
Pancreatic Cancer1 trial
Unspecified1 trial
High-dose ICE With Amifostine
Completed·—·Phase 2·NCT00003657·24 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 30, 1988
IFEX
NDA NDA019763
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ifex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for ifosfamide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBaxter Healthcare Corporation